Kazia Therapeutics Ltd (KZIA) Actualités

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form F-1 - Registration statement for certain foreign private issuers

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with...

Form D - Notice of Exempt Offering of Securities

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors